---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-205557"
form_type: "8-K"
ticker: "MCRB"
cik: "0001609809"
company_name: "Seres Therapeutics, Inc."
filed_at: "2023-08-08T23:59:59+00:00"
generated_at: "2026-06-12T02:04:36.060625+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Seres reports Q2 2023 net income of $46.6M on $125M VOWST milestone; early launch demand strong

## Summary
- Net income $46.6M vs net loss $64.7M YoY; $125M milestone from Nestlé upon FDA approval of VOWST.
- VOWST net sales $1.6M in first partial quarter; 610 prescription forms, 282 patient starts from 480+ HCPs.
- Cash $229.5M; new $250M Oaktree debt facility, drew $110M at close, $53.4M to retire prior debt.
- SER-155 Phase 1b Cohort 1: favorable tolerability, reduced ESKAPE pathogen domination; Cohort 2 data mid-2024.
- R&D expense $46.8M, G&A $28.1M; VOWST commercial mfg costs to capitalize post-approval.

## SEC filing metadata
- accession: 0001193125-23-205557
- form_type: 8-K
- ticker: MCRB
- cik: 0001609809
- company_name: Seres Therapeutics, Inc.
- filed_at: 2023-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1609809/000119312523205557/0001193125-23-205557-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1609809/000119312523205557/d541674d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-205557
- JSON: https://secwatch.observer/filing/0001193125-23-205557.json
- Plain text: https://secwatch.observer/filing/0001193125-23-205557.txt

## Key facts
- Earnings Releases
  Seres Therapeutics, Inc. reported financial results for the quarter ended June 30, 2023.
  - Period: the quarter ended June 30, 2023
  - Result: reported results
  source text: On August 8, 2023, Seres Therapeutics, Inc. (the "Company") announced its financial results for the quarter ended June 30, 2023 and provided operational updates.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1609809/000119312523205557/0001193125-23-205557-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.